3/5
08:34 am
mirm
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus [Yahoo! Finance]
Medium
Report
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus [Yahoo! Finance]
3/5
08:00 am
mirm
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Medium
Report
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
3/4
10:10 am
mirm
Mirum Pharmaceuticals (MIRM) was given a new $126.00 price target by Evercore Inc.
Medium
Report
Mirum Pharmaceuticals (MIRM) was given a new $126.00 price target by Evercore Inc.
2/28
01:40 pm
mirm
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News [Yahoo! Finance]
Low
Report
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News [Yahoo! Finance]
2/26
01:36 pm
mirm
Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $115.00 to $117.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $115.00 to $117.00. They now have a "buy" rating on the stock.
2/26
12:11 pm
mirm
Mirum Pharmaceuticals (MIRM) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Mirum Pharmaceuticals (MIRM) had its "outperform" rating reaffirmed by Leerink Partners.
2/26
12:11 pm
mirm
Mirum Pharmaceuticals (MIRM) had its "outperform" rating reaffirmed by Evercore Inc.
Low
Report
Mirum Pharmaceuticals (MIRM) had its "outperform" rating reaffirmed by Evercore Inc.
2/26
10:52 am
mirm
Mirum Pharmaceuticals (MIRM) had its price target lowered by Royal Bank Of Canada from $130.00 to $128.00. They now have an "outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals (MIRM) had its price target lowered by Royal Bank Of Canada from $130.00 to $128.00. They now have an "outperform" rating on the stock.
2/26
09:55 am
mirm
Mirum Pharmaceuticals (MIRM) had its price target raised by Stifel Nicolaus from $98.00 to $125.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals (MIRM) had its price target raised by Stifel Nicolaus from $98.00 to $125.00. They now have a "buy" rating on the stock.
2/26
09:55 am
mirm
Mirum Pharmaceuticals (MIRM) had its price target lowered by Citizens Jmp from $140.00 to $132.00. They now have a "market outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals (MIRM) had its price target lowered by Citizens Jmp from $140.00 to $132.00. They now have a "market outperform" rating on the stock.
2/26
09:31 am
mirm
Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals) [Seeking Alpha]
Medium
Report
Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals) [Seeking Alpha]
2/25
05:58 pm
mirm
Mirum (MIRM) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
High
Report
Mirum (MIRM) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
05:14 pm
mirm
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update [Yahoo! Finance]
High
Report
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update [Yahoo! Finance]
2/25
04:01 pm
mirm
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
High
Report
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
2/23
04:11 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/23
04:01 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2/19
07:26 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
2/18
04:16 pm
mirm
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 [Yahoo! Finance]
2/18
04:01 pm
mirm
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
Low
Report
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
2/17
06:05 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $130.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $130.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
2/10
10:45 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/5
08:51 am
mirm
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Medium
Report
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
2/5
08:00 am
mirm
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Medium
Report
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
2/3
07:17 am
mirm
Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]
Low
Report
Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]
1/31
03:29 pm
mirm
Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]
Low
Report
Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]